In the last decade remarkable progress has been made in the treatment of metastatic colorectal cancer due to the introduction of oxaliplatin and irinotecan in clinical practice. The addition of biological agents seems to offer a chance to further enhance the activity of conventional chemotherapy. Cetuximab, a chimeric mouse-human monoclonal antibody targeting the extracellular domain of the epidermal growth factor receptor (EGFR), has shown low but detectable activity when employed in pretreated patients either as a single agent or in combination with irinotecan. Cetuximab in combination with irinotecan has been registered in the USA and Europe for the treatment of patients with metastatic colorectal cancer expressing the EGFR after failure of prior irinotecan-based cytotoxic therapy. The role of cetuximab in first-line therapy is still investigational. Some phase II trials assessing cetuximab plus chemotherapy demonstrated a high objective response rate and promising results in terms of time to progression and overall survival; data from phase III trials are pending. Further studies are needed to investigate the efficacy of cetuximab in combination with conventional chemotherapy in the adjuvant/neoadjuvant setting and to define criteria for a better selection of patients for this type of treatment. (Int J Biol Markers 2007; 22 (suppl 4): S62-70)
INTRODUCTION
The introduction of targeted therapies into clinical practice in recent years seems to offer incremental benefits in the treatment of metastatic colorectal cancer (mCRC) when they are employed in combination with optimal chemotherapy. Cetuximab (Erbitux) and bevacizumab (Avastin) are the most widely tested antibodies in this setting to date and have been approved in the USA and Europe, albeit with different indications. In this paper we focus on cetuximab and its role in the treatment of mCRC.
CETUXIMAB
Cetuximab is a chimeric mouse-human monoclonal antibody targeting the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the binding of its natural ligands (epidermal growth factor and transforming growth factor alpha) and triggering the internalization of the receptor (1) . The EGFR is a transmembrane tyrosine kinase and is 1 of the 4 members of the HER receptor family; it is overexpressed in a number of solid tumors including colon adenocarcinoma. In some studies its overexpression has been correlated with disease progression, poor prognosis and reduced sensitivity to chemotherapy (2, 3) . Several strategies have been developed to target EGFR including the use of mon-oclonal antibodies and small-molecule tyrosine kinase inhibitors (4, 5) . Cetuximab is the most widely investigated monoclonal antibody in the treatment of mCRC patients and has shown low but detectable intrinsic activity when employed as a single agent in pretreated patients.
CETUXIMAB MONOTHERAPY IN PRETREATED PATIENTS
The efficacy of single-agent cetuximab in patients with pretreated mCRC and expressing the EGFR was evaluated in 3 non-randomized and 1 randomized trial (BOND study, single-agent arm) (6) (7) (8) (9) . Patient and tumor characteristics were comparable across studies and the patient populations were similar to those of other clinical studies in terms of performance status (PS) and adequate organ function. The results were similar in terms of objective response rate (RR), disease control, median time to progression (TTP), and median overall survival (OS), which ranged from 8% to 12%, 32% to 50%, 1.4 to 4.2 months and 6.4 to 7.0 months, respectively (Tab. I). Interestingly, in one of these studies (7) , although patients had received 2 to 9 lines of therapy, the RR and OS were not significantly influenced by the number of previous lines of therapy or the sequence of the agents. Moreover, 2 objective responses were observed among 9 erroneously enrolled EGFR-negative patients, suggesting that the recommended practice of testing EGFR status by immuno-S63 histochemistry to select patients for cetuximab therapy is inappropriate and other predictive tests are needed. Further evidence for the activity of cetuximab comes from another investigational trial testing different doses of the drug. This study included a standard arm in which the monoclonal antibody was administered at a loading dose of 400 mg/m² followed by 250 mg/m² weekly, and 2 experimental arms with cetuximab administered at 250 mg/m² or 350 mg/m² weekly, without the higher initial dose (10) . Among the 49 enrolled patients, the objective RRs were 7.1%, 22.2% and 17.7%, respectively, the difference being mainly related to the different PS.
The safety profile of single-agent cetuximab was good. The most common adverse events (all grades) were acnelike rash (83%), asthenia/malaise (49%), fever (33%), nausea (29%), diarrhea (28%), constipation (28%), abdominal pain (25%), and headache (25%). High-grade adverse events included acnelike rash and asthenia, affecting about 10% of patients, abdominal pain (7%), vomiting (3%), nausea and diarrhea (2%), and anemia (3%).
CETUXIMAB COMBINATION THERAPY IN PRETREATED PATIENTS
Preclinical studies demonstrated synergistic tumor growth inhibition or tumor regression when cetuximab was administered in combination with irinotecan (CPT-11) (11) . The efficacy of this combination in patients with mCRC progressing on or after irinotecan-based regimens was initially evaluated in 1 nonrandomized and 1 randomized phase II trial (BOND study, combination arm) (9, 12) (Tab. II). The first was a US trial that used the combination of the 2 drugs in 138 pretreated patients, employing irinotecan at the same dose and schedule as the one patients had progressed on. An overall RR of 13%, a disease control rate of 53%, a median TTP of 2.6 months, and a median OS of 7.7 months were observed. The BOND study was a randomized phase II trial comparing cetuximab plus irinotecan to cetuximab alone in pretreated mCRC patients. In this study 329 patients whose disease had progressed during or within 3 months after treatment with an irinotecan-based regimen and whose tumors expressed any level of EGFR were randomized 2:1 to receive either cetuximab (400 mg/m² loading dose followed by 250 mg/m² weekly) plus irinotecan (same schedule as before) or cetuximab alone. The intent-totreat analysis showed a statistically significantly higher overall RR (23% vs 11%, p=0.007) and disease control (56% vs 32%, p<0.001) with a longer TTP (4.1 vs 1.5 months, p<0.001) in favor of the combination. The median OS was also longer for cetuximab plus irinotecan (8.6 vs 6.9 months) but the difference was not statistically significant (p=0.48) (Tab. III). This may be due to 2 reasons: 1) the study was not powered to demonstrate a survival benefit, and 2) patients could switch from monotherapy to the combination arm at disease progression. The efficacy of cetuximab plus irinotecan in terms of objective response was independent of the number of prior chemotherapy lines, with a response rate of 17%, 25% and 24%, respectively, when 1, 2 or ≥3 lines had been administered. Interestingly, subgroup analyses indicated preserved efficacy for the combination treatment in patients strictly refractory to irinotecan and in those having undergone previous oxaliplatin (L-OHP) treatment. Another interesting aspect was that a skin reaction during treatment was predictive of outcome: the RR was 6% for patients without skin reactions, 20% for patients with mild skin reactions, and 55% for patients with severe skin reactions. In patients with skin reactions ≥2 (NCI-CTC criteria v 2.0) the median survival was 10.8 months compared to 3.0 months in patients without skin reactions. Similar data concerning the activity and efficacy of cetuximab plus irinotecan in patients pretreated with irinotecan-based schedules are derived from the MABEL study (13) . A response rate of 20% and a tumor control rate of 45% were observed in 1147 enrolled patients; the median OS of 9.2 months was comparable to the 8.6 months of the BOND study. The progression-free survival (PFS) and the OS at 12, 24, 36 and 48 weeks were 61%, 34%, 17% and 6% and 68%, 39%, 22% and 16%, respectively.
Two randomized phase III trials recently concluded their patient accrual. The first is a Canadian study that randomized 572 EGFR-expressing patients pretreated with oxaliplatin-based and irinotecan-based schedules to receive cetuximab plus best supportive care (BSC) or BSC alone. The second is the EPIC study, a large phase III trial exploring the activity of cetuximab plus irinotecan with respect to irinotecan alone in patients pretreated with oxaliplatin-based regimens. Safety analyses concerning the first 400 patients showed data similar to those of previous experiences (14) .
Due to recent changes in clinical practice which have resulted in a move away from the use of irinotecan in combination with fluorouracil (5FU) plus folinic acid (FA) to oxaliplatin-based therapy in the first-line setting, we have few data regarding the activity of cetuximab in combination with oxaliplatin in pretreated patients. The accrual of the EXPLORE study was recently stopped after the enrollment of the first 102 patients (15) . In this study mCRC patients who failed on first-line irinotecan-based therapy were randomized to receive cetuximab plus FOLFOX-4 or FOLFOX-4 alone. Due to inconsistencies between the median TTP (difference of 9 days) and because EXPLORE was not powered to show any difference in 102 patients, the study cannot be used to draw any conclusions from the comparison between the 2 arms.
As a result of the data obtained so far, cetuximab in combination with irinotecan has been registered in the USA and Europe for the treatment of mCRC patients expressing the EGFR after failure of previous irinotecanbased cytotoxic therapy.
CETUXIMAB AS FIRST-LINE THERAPY
While cetuximab has established activity in the salvage setting, its role in first-line therapy is still investigational. However, preliminary data from phase II trials are very encouraging.
Five phase II trials (1 randomized, 4 nonrandomized) evaluated the activity of cetuximab combined with irinotecan-based regimens (16) (17) (18) (19) (20) . Different schedules were employed: weekly administration of irinotecan plus bolus 5FU/FA, weekly administration of irinotecan plus 24-hour continuous infusion of 5FU/FA, or biweekly irinotecan plus 5FU/FA administered as 48-hour continuous infusion. The observed RR was in the range of 44-67%, with disease control ranging from 76% to 96% and a median TTP of about 10 months (Tab. IV). Recently the CRYSTAL study, a randomized phase III trial testing cetuximab plus FOLFIRI versus FOLFIRI alone, met the primary end point of progression free survival (PFS). The data will be presented at the next ASCO meeting and are expected to clarify the possible role of this combination in first-line therapy.
Because of the similar results obtained with FOL-FOX-4 and FOLFIRI regimens in mCRC (21, 22) , 5 phase II studies (1 randomized, 4 nonrandomized) investigated the activity of the combination of cetuximab plus FOL-FOX-4 (20, 23-26) (Tab. V). A French-Spanish trial enrolled 43 patients who were treated with the combination of cetuximab plus FOLFOX-4. An objective RR of 72%, a disease control rate of 95%, a median TTP of 12.3 months, and a median OS of 30 months were recently reported (23) . Interestingly, 10 patients (23%) with initially unresectable metastases underwent surgery with curative intent.
These data were confirmed by a large phase II trial by the Gruppo Oncologico dell'Italia Meridionale (GOIM) that enrolled 70 unselected patients who were treated with the same combination (24) . Three complete (4.5%) and 39 partial (58.2%) confirmed responses were observed in 67 evaluable patients for an overall RR of 62.7%; 21 patients (31.3%) had stable disease (SD), resulting in a disease control rate of 94% (Tab. VI). These data are of particular interest considering that the population was unselected, as shown by the high percentage of synchronous metastases and multiple sites of disease (84% and 37%, respectively) in the enrolled patients. Furthermore, among the 33 patients with initially unresectable liver disease, 7 (21%) underwent resection after the treatment. These data confirm the possibility to employ this combination in the neoadjuvant setting.
Data from an ongoing randomized trial of neoadjuvant therapy (EMR-604 CELIM study) are pending. In this study, patients with unresectable liver metastases are randomized to receive 8 cycles of cetuximab + FOLFIRI or cetuximab + FOLFOX before being re-evaluated for resectability.
Overall, the results obtained with the combination of cetuximab plus FOLFOX in terms of activity are in the range of 54-72%, with a disease control rate of 86-95% and a median TTP ranging from 8 to 12 months. These re-sults are similar to those obtained with the combination of cetuximab and irinotecan-based regimens. Both combinations seem to produce better results than chemotherapy alone. Also in a prematurely closed phase II randomized trial comparing FOLFIRI/FOLFOX ± cetuximab the RR was higher for the regimens including the monoclonal antibody than for those using chemotherapy alone, 52% vs 38% (p=0.029) (20) .
However, it must be taken into account that these data are derived from phase II studies while we are waiting for the results of ongoing phase III trials such as the OPUS study, which compares cetuximab + FOLFOX with FOLFOX alone; the COIN study, a 3-arm trial in which patients are randomized to receive cetuximab + FOLFOX or FOLFOX alone or FOLFOX stop-and-go after 12 cycles; and the NORDIC VII study in which patients are randomized to receive continuous FLOX or continuous FLOX + cetuximab or intermittent FLOX + continuous cetuximab. Interestingly, in the COIN study EGFR positivity was not mandatory. The results of these ongoing studies will elucidate the potential role of these combinations in first-line treatment.
With regard to safety, the addition of cetuximab to irinotecan or oxaliplatin-based regimens does not increase the toxicity: more grade 3-4 neutropenia (33% vs 21%) and neurotoxicity (16-25% vs 0) were observed for irinotecan-based and oxaliplatin-based schedules, respec- tively, while the incidence of diarrhea was similar. The peculiar cutaneous toxicity associated with cetuximab was observed in all these trials, with the highest grades ranging from 6% to about 30% (23) (24) (25) (26) . The introduction of oral fluoropyrimidines into clinical practice offered another chance in the treatment of CRC. In a comprehensive analysis of 2 randomized trials, capecitabine (Xeloda) was demonstrated to have better antitumor activity, similar efficacy, and an improved safety profile when compared to FU/FA in the treatment of patients with advanced disease (27) .
Preliminary data from an AIO randomized phase II trial comparing irinotecan (200 mg/m²) + capecitabine (800 mg/m² bid) + cetuximab to oxaliplatin (130 mg/m²) plus capecitabine (1000 mg/m² bid) + cetuximab reported an RR of 40.7% and 68.0%, respectively (p=0.058) with similar disease control (88.9% vs 92.0%) (28) . However, the used dosage of capecitabine in combination with irinotecan seems to be inappropriate. In another randomized phase II study (SAKK) the combination of oxaliplatin and capecitabine (XELOX) alone was compared to XELOX plus cetuximab in 74 enrolled patients (37 in both arms) (29) . The observed RR and disease control at 18 weeks were 30% and 51%, and 46% and 65%, respectively. However, also for these combinations further study is needed.
MONOCLONAL ANTIBODIES IN COMBINATION: CETUXIMAB PLUS BEVACIZUMAB
Preclinical data showed that cetuximab can reduce the levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (b-FGF) and interleukin-8 (IL-8) (30) . In view of these data, a phase II trial (BOND-2 study) randomized irinotecan-pretreated patients to re-ceive cetuximab + bevacizumab + irinotecan or cetuximab + bevacizumab alone (31) . Eighty-one patients were enrolled (41 and 40 in each arm) and RRs of 37% vs 20% and a median TTP of 7.9 vs 5.6 months were observed. The main grade 3-4 toxicities were diarrhea (24%), neutropenia (22%), asthenia (10%) and skin reactions (17%).
Two large phase III trials are ongoing: the CALGB/SWOG 80405 study (primary end point OS, planned accrual more than 2000 patients) in which patients are randomized to receive FOLFIRI/FOLFOX-6 plus cetuximab or bevacizumab or both, and the CAIRO II study (planned accrual 750 patients) in which patients are randomized to receive XELOX + bevacizumab + cetuximab or XELOX + bevacizumab alone.
CUTANEOUS TOXICITY
The tolerability profile for cetuximab is characterized by a unique group of skin reactions such as an acneiform eruption, xerosis and eczema related to the inhibition of the EGFR in proliferating, undifferentiated keratinocytes of the basal layers of the epidermis. These side effects are similar to those of other EGRF inhibitors.
A pustular or maculopapular follicular rash often referred to as acneiform and usually distributed in the seborrhoic areas (upper torso, face, neck and scalp) ( Fig. 1-3) is the most common cutaneous side effect associated with cetuximab treatment (32, 33) . The acneiform eruption is not associated with comedones; hence it appears to represent a clinical entity that is different from classical acne vulgaris. Clinically, the acneiform lesions present as pruritic, erythematous follicular papules that often evolve into pustules; the aggregation of these pustules may further evolve into yellow crusts. Areas of dif- fuse erythema with follicular papulopustules or seborrheic dermatitis can affect the face; sometimes the facial rash is accompanied by an edematous erythema. In rare cases the cutaneous inflammation progresses to necrosis with ulcerations and black eschar formation (Fig. 4) . The onset of the rash is usually within 1-3 weeks of the start of therapy although in exceptional cases it may occur much later. Approximately 80-90% of patients experience mild or moderate rash and about 20-30% are affected by higher grades of skin toxicity, especially when cetuximab is given in combination with chemotherapy. All these dermatological effects are reversible and generally resolve without sequelae on cessation of therapy. About 30-35% of patients develop xerosis after several weeks of treatment (Fig. 2) ; this condition can progress to a classical eczema with secondary complications such as bacterial superinfections. The tips of the fingers and toes become dry and scaly and this can be accompanied by painful fissures which may also occur in the nail folds and across the knuckles (34) .
Paronychia may occur in about 10% of patients ( Fig.  5, 6 ). It presents as a swelling of the lateral nail folds of the toes and fingers and can be very painful. It is occasionally associated with pyogenic granuloma-like lesions. All these skin effects may constitute a significant obstacle to patient compliance with treatment.
The therapeutic management of these cutaneous side effects is not standardized and often based on local practice. However, some common principles apply. For example, patients can minimize the extent or intensity of the eruption by avoiding sunbathing or direct exposure to strong sunlight. Grade 1 rash on the face may be treated with benzoyl peroxide gel or cream; when it occurs on the chest or back, salicylic acid in alcoholic lotion can be used. Additional topical menthol cream or an oral antihistamine or a combination of the 2 may be effective in grade 2 toxicity. Oral tetracyclines and corticosteroids are of limited efficacy. In cases of grade 3 rash patients should continue with topical applications while cetuximab treatment should be delayed. In cases of grade 4 cutaneous toxicity, further treatment with EGFR inhibitors should not be considered. The use of emollients is generally effective for dry skin, while eczema may be treated with topical low-dose corticosteroids. The treatment of paronychia is difficult: some dermatologists prescribe a drying paste containing an antiseptic (chlorhexidine) and oral antibiotics are recommended in cases of bacterial infection. Silver nitrate may be appropriate for the treatment of associated pyogenic granuloma (35, 36) .
OPEN QUESTIONS

Adjuvant treatment
Two large phase III trials with a similar study design are ongoing: PETACC-8 and NCCTG-147. In these trials patients with stage III colon cancer are randomized to receive FOLFOX-4 plus cetuximab or FOLFOX-4 alone. The planned accrual is 2000 and 2300 patients, respectively. The results of these studies will clarify whether cetuximab has a role to play in the adjuvant setting. 
EGFR-negative patients
To date, EGFR positivity by immunohistochemical analysis of the tumor specimen has been mandatory for the clinical use of cetuximab. However, in one study 2 major responses among 9 patients with EGFR-negative CRC were observed (7) . Moreover, in a retrospective analysis, 4 of 16 EGFR-negative patients had major responses to cetuximab (37) . These observations, despite the limitation of the small number of patients analyzed, demonstrate that patients with EGFR-negative mCRC may respond to cetuximab like EGFR-positive patients. These observations imply that EGFR analysis by current immunohistochemical techniques does not have any predictive value and should not be used to select patients for cetuximab therapy.
Optimal dosage
The standard dose of cetuximab employed in clinical experiences is a 400 mg/m² loading dose followed by 250 mg/m² weekly. This schedule is inconvenient because of the frequency of drug administration. The results of a phase I study exploring the pharmacokinetic and pharmacodynamic characteristics of a biweekly administration of cetuximab indicated that a dose of 500 mg/m² was well tolerated without differences in EGFR inhibition (38) . In another trial, the EVEREST study, the weekly dose of cetuximab was escalated to 500 mg/m² without any particular side effects (39) .
Selection of patients
Considering the costs of novel therapies, improved selection of patients with a better chance of responding to a specific treatment seems appropriate. One study an-alyzed the relationship between cetuximab treatment and KRAS mutational status (40) . Among the 30 patients treated with cetuximab, 11 responded and none of them had KRAS mutations, while 13 of the 19 nonresponders had KRAS mutations (p=0.0003). The difference remained significant also when patients treated with cetuximab as first-line were removed (0/8 vs 13/19, p=0.002). Future molecular biology studies will have to establish which patients could benefit from these treatments.
CONCLUSIONS
From our analysis of the literature data we can draw the following conclusions. Single-agent cetuximab has intrinsic activity in the treatment of mCRC. In combination with irinotecan-based regimens, cetuximab has a well-defined role as salvage treatment. Encouraging preliminary results from phase II trials suggest that cetuximab can be used in first-line treatment; pending data from phase III trials will further clarify its role. Future studies will indicate whether cetuximab can be used in the adjuvant setting. Finally, molecular biology studies are needed to define criteria for the selection of patients who are likely to respond to cetuximab treatment. 
